Epigenetic and genomic changes have been identified as potential drivers of resistance to the sotorasib combination therapy in KRAS G12C colorectal cancer. Data from the study revealed a diverse range of emergent alteration patterns across the treatment arms, with notable numerical differences in ERBB2 and MET alterations. While statistically insignificant, the rate of ERBB2 alterations […]